D-4F and L-5F decrease hepatic mRNA level of genes involved in gluconeogenesis. by Kristine C. McGrath (8269155)

D-4F and L-5F decrease hepatic mRNA level of genes involved in inflammation. by Kristine C. McGrath (8269155)

D-4F and L-5F decrease hepatic mRNA levels of genes involved in lipogenesis. by Kristine C. McGrath (8269155)

In combination with our previous report [<b>5</b>], we have created an overview of the early molecular response comparing woven to lamellar bone formation. by Jennifer A. McKenzie (190618)

Decrease in BMP2-induced Smad1/5/8 phosphorylation due to Panx3 siRNA. by Tsutomu Iwamoto (715969)

Spatial information is significantly decreased in dCA1 and vCA1 in APP/PS1 mice. by Udaysankar Chockanathan (18510288)

“…(B) In dCA1, spatial information was decreased in APP/PS1 mice relative to C57BL/6 controls (mean ± std: C57BL/6 = 0.132 ± 0.048, APP/PS1 = 0.128 ± 0.051, p < 0.005, two-sided Wilcoxon rank-sum test, n_C57BL/6 = 305 units from 5 recording sessions, n_APP/PS1 = 180 units from 4 recording sessions). …”

Pairwise correlations in APP/PS1 mice are decreased in dCA1, but increased in vCA1. by Udaysankar Chockanathan (18510288)

No contribution of TGF-α, protein phosphatase 5 or protein kinase A to decreased levels of secreted Hsp90. by Stefan Tukaj (439533)

Population entropy in APP/PS1 mice is decreased in dCA1, but increased in vCA1. by Udaysankar Chockanathan (18510288)

Spatial stability is decreased in APP/PS1 mice in both dCA1 and vCA1. by Udaysankar Chockanathan (18510288)

“…<p>(A) In dCA1, stability score was significantly decreased in APP/PS1 mice relative to C57BL/6 mice (mean ± std: C57BL/6 = -0.009 ± 0.292, APP/PS1 = -0.1845 ± 0.256, p < 10⁻⁶, two-sided Wilcoxon rank-sum test, n_C57BL/6 = 295 units from 5 recording sessions, n_APP/PS1 = 167 units from 4 recording sessions). …”

<i>Syx5</i> suppression in human cells decreases copper accumulation but does not affect rate of turnover. by Melanie Norgate (234832)

WCESP (2 mg/ml) decreases <i>V</i>. <i>cholerae</i> cell-surface hydrophobicity. by Daniel B. Pederson (604306)

Decreased motor neuron survival in E18.5 GAD67-deficient (−/−) hypoglossal and phrenic motor nuclei. by Matthew J. Fogarty (283288)

Botulinum toxin A (3.5 U/kg) decreases dural extravasation in IoNC injured rats. by Boris Filipović (336089)

Archazolid decreases the activity and expression of cathepsin B in endothelial cells. by Betty Luong (5738027)

Retnla overexpression decreased the levels of IL-4, IL-5, and IL-13 in OVA-induced asthmatic lung. by Mi-Ran Lee (664596)

Acute intestinal inflammation transiently decreases frequency of colonic LP CD5⁺ B cells. by Yoshiyuki Mishima (842248)

List of Included studies. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

The search strategy in three databases. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

A summary of the included study characteristics. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”